PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB 100 million (USD 13.8 million) in a recent financing round. This capital injection, which includes investment from Sunland Fund and other financial backers, will be directed towards the construction of the renewable Living Primary Cancer Cell Bank (LPCB).
Investment Details and Objectives
The proceeds from this financing round will be utilized to advance PRECEDO’s cutting-edge projects in the field of cell engineering. The primary focus is the development of the Living Primary Cancer Cell Bank, which aims to provide a renewable resource for cancer research and treatment development.
PRECEDO’s Technological Edge
PRECEDO is renowned for its proprietary technologies in the realm of renewable cancer primary cell technology systems and gene-regulated engineering cell technology systems. The company’s assets include a renewable cancer primary cell biological sample library, a BaF3 cancer kinase target engineering cell library, and a specific gene phenotype engineering series of cells. These resources position PRECEDO at the forefront of cell engineering and cancer research.- Flcube.com
